Published in Psychiatr Serv on February 01, 2007
Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review. J Subst Abuse Treat (2008) 2.42
Statewide adoption and initial implementation of contingency management for substance-abusing adolescents. J Consult Clin Psychol (2008) 2.18
Organizational Readiness for Change and opinions toward treatment innovations. J Subst Abuse Treat (2007) 2.14
Attitudes toward the integration of smoking cessation treatment into drug abuse clinics. J Subst Abuse Treat (2006) 2.08
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
What is usual about "treatment-as-usual"? Data from two multisite effectiveness trials. J Subst Abuse Treat (2008) 1.45
Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption. J Subst Abuse Treat (2008) 1.40
Counselor attitudes toward the use of motivational incentives in addiction treatment. Am J Addict (2010) 1.33
Primary care and public health services integration in Brazil's unified health system. Am J Public Health (2012) 1.32
Leadership, burnout, and job satisfaction in outpatient drug-free treatment programs. J Subst Abuse Treat (2009) 1.31
Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. J Addict Med (2010) 1.15
Contingency management in substance abuse treatment: a structured review of the evidence for its transportability. Drug Alcohol Depend (2011) 1.14
Treatment process, alliance and outcome in brief versus extended treatments for marijuana dependence. Addiction (2010) 1.12
Therapist predictors of treatment delivery fidelity in a community-based trial of 12-step facilitation. Am J Drug Alcohol Abuse (2013) 1.11
From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat (2010) 1.04
Substance abuse treatment providers' involvement in research is associated with willingness to use findings in practice. J Subst Abuse Treat (2010) 1.00
Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations. J Subst Abuse Treat (2012) 0.98
Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection. Am J Drug Alcohol Abuse (2011) 0.97
Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach. Psychol Serv (2009) 0.96
Substance abuse treatment counselors and tobacco use: a comparison of comprehensive and indoor-only workplace smoking bans. Nicotine Tob Res (2010) 0.96
Comparing credentialing requirements of substance abuse treatment staff by funding source. J Subst Abuse Treat (2007) 0.94
Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communities. Adm Policy Ment Health (2014) 0.94
Identifying provider beliefs related to contingency management adoption using the contingency management beliefs questionnaire. Drug Alcohol Depend (2011) 0.93
Predicting outpatient treatment entry following detoxification for injection drug use: the impact of patient and program factors. J Subst Abuse Treat (2010) 0.90
Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat (2014) 0.89
A multilevel approach to predicting community addiction treatment attitudes about contingency management. J Subst Abuse Treat (2011) 0.88
Addiction treatment centers' progress in preparing for health care reform. J Subst Abuse Treat (2013) 0.87
Community-based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. Eval Program Plann (2011) 0.87
Community treatment adoption of contingency management: a conceptual profile of U.S. clinics based on innovativeness of executive staff. Int J Drug Policy (2012) 0.86
Evaluating training methods for transporting contingency management to therapists. J Subst Abuse Treat (2013) 0.85
Disseminating contingency management: impacts of staff training and implementation at an opiate treatment program. J Subst Abuse Treat (2013) 0.85
Availability and capacity of substance abuse programs in correctional settings: A classification and regression tree analysis. Drug Alcohol Depend (2009) 0.84
First Evaluation of a Contingency Management Intervention Addressing Adolescent Substance Use and Sexual Risk Behaviors: Risk Reduction Therapy for Adolescents. J Subst Abuse Treat (2016) 0.82
Community opioid treatment perspectives on contingency management: perceived feasibility, effectiveness, and transportability of social and financial incentives. J Subst Abuse Treat (2013) 0.82
Don'T forget the workforce. Psychiatr Serv (2007) 0.82
Implementing substance abuse group therapy clinical trials in real-world settings: challenges and strategies for participant recruitment and therapist training in the Women's Recovery Group Study. Am J Addict (2014) 0.82
Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. Ann N Y Acad Sci (2014) 0.81
Counselor Attitudes Toward Contingency Management for Substance Use Disorder: Effectiveness, Acceptability, and Endorsement of Incentives for Treatment Attendance and Abstinence. J Subst Abuse Treat (2015) 0.81
The substance abuse counseling workforce: education, preparation, and certification. Subst Abus (2011) 0.80
Addressing substance abuse and violence in substance use disorder treatment and batterer intervention programs. Subst Abuse Treat Prev Policy (2012) 0.79
Acceptability of contingency management among clinicians and clients within a co-occurring mental health and substance use treatment program. Am J Addict (2013) 0.79
Legislating clinical practice: counselor responses to an evidence-based practice mandate. J Psychoactive Drugs (2011) 0.79
Counselor attitudes toward and use of evidence-based practices in private substance use disorder treatment centers: a comparison of social workers and non-social workers. Health Soc Work (2012) 0.79
Adoption of practice guidelines and assessment tools in substance abuse treatment. Subst Abuse Treat Prev Policy (2010) 0.79
Treatment length and outcomes among adolescents: a secondary data analysis. Subst Abuse Treat Prev Policy (2012) 0.78
I heard about it from a friend: assessing interest in buprenorphine treatment. Subst Abus (2014) 0.78
The Substance Abuse Treatment Workforce of South Africa. Int J Ment Health Addict (2009) 0.75
Transdisciplinary collaboration and endorsement of pharmacological and psychosocial evidence-based practices by medical and psychosocial substance abuse treatment providers in the United States. Drugs (Abingdon Engl) (2013) 0.75
Predictive Validity of Addiction Treatment Clinicians' Post-Training Contingency Management Skills for Subsequent Clinical Outcomes. J Subst Abuse Treat (2015) 0.75
Randomized Trial of Computerized Cognitive Behavioral Therapy for Alcohol Use Disorders: Efficacy as a Virtual Stand-Alone and Treatment Add-On Compared with Standard Outpatient Treatment. Alcohol Clin Exp Res (2016) 0.75
Workforce professionalism in drug treatment services: impact of California's Proposition 36. J Subst Abuse Treat (2010) 0.75
Finding harmony so the music plays on: pragmatic trial design considerations to promote organizational sustainment of an empirically-supported behavior therapy. Addict Sci Clin Pract (2016) 0.75
The employment of nurses in publicly funded substance abuse treatment programs. J Addict Nurs (2012) 0.75
Assessing organizational readiness for change. J Subst Abuse Treat (2002) 7.75
Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry (2005) 6.97
A conceptual framework for transferring research to practice. J Subst Abuse Treat (2002) 6.76
Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend (2005) 4.65
Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry (2006) 4.64
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction (2005) 4.14
Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry (2004) 3.72
Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat (2003) 2.91
Staff beliefs about addiction treatment. J Subst Abuse Treat (2001) 2.87
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85
A national study of the substance abuse treatment workforce. J Subst Abuse Treat (2003) 1.92
Design and implementation of microarray gene expression markup language (MAGE-ML). Genome Biol (2002) 16.75
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinformatics (2006) 7.53
Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry (2005) 6.97
Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35
Pattern separation in the human hippocampal CA3 and dentate gyrus. Science (2008) 5.56
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA (2008) 3.64
The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol (2007) 3.55
Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction (2005) 2.78
Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial. J Acquir Immune Defic Syndr (2008) 2.78
Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend (2005) 2.66
Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend (2007) 2.63
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. Am J Psychiatry (2009) 2.44
Greater prevalence and incidence of dementia in older veterans with posttraumatic stress disorder. J Am Geriatr Soc (2010) 2.38
Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol (2009) 2.26
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Organizational Readiness for Change and opinions toward treatment innovations. J Subst Abuse Treat (2007) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction (2002) 1.94
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis (2007) 1.93
Smoking status as a clinical indicator for alcohol misuse in US adults. Arch Intern Med (2007) 1.92
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials (2010) 1.72
Image-based estimation of ventricular fiber orientations for personalized modeling of cardiac electrophysiology. IEEE Trans Med Imaging (2012) 1.72
Cognition, commitment language, and behavioral change among cocaine-dependent patients. Psychol Addict Behav (2008) 1.72
Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol (2003) 1.71
Addiction treatment agencies' use of data: a qualitative assessment. J Behav Health Serv Res (2006) 1.66
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J (2003) 1.64
Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med (2010) 1.64
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther (2003) 1.63
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63
Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend (2011) 1.62
Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat (2006) 1.61
Rising national prevalence of life-limiting conditions in children in England. Pediatrics (2012) 1.59
Smoking cessation treatment in community-based substance abuse rehabilitation programs. J Subst Abuse Treat (2007) 1.57
The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J Subst Abuse Treat (2008) 1.56
Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet (2007) 1.54
Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant (2008) 1.52
Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities. Am J Addict (2008) 1.52
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 1.51
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis (2002) 1.49
Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry (2005) 1.48
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48
Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res (2006) 1.47
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther (2007) 1.46
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology (2011) 1.46
Reduction of quantity smoked predicts future cessation among older smokers. Addiction (2004) 1.46
Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA (2012) 1.45
Zero-inflated and hurdle models of count data with extra zeros: examples from an HIV-risk reduction intervention trial. Am J Drug Alcohol Abuse (2011) 1.44
The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophr Res (2007) 1.44
The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med (Berl) (2006) 1.42
Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol (2007) 1.41
More on cultivating veterinarian-scientists. J Am Vet Med Assoc (2010) 1.40
Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry (2014) 1.40
FuGE: Functional Genomics Experiment Object Model. OMICS (2006) 1.39
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. Contemp Clin Trials (2011) 1.38
The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment. J Subst Abuse Treat (2005) 1.37
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat (2002) 1.36
The Oak Ridge Polycystic Kidney mouse: modeling ciliopathies of mice and men. Dev Dyn (2008) 1.36
Does glycemic variability impact mood and quality of life? Diabetes Technol Ther (2012) 1.35
Lead toxicity in a 14-year-old female with retained bullet fragments. Pediatrics (2006) 1.34
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend (2005) 1.31
The link between post-traumatic stress disorder and physical comorbidities: a systematic review. Psychiatr Q (2009) 1.31
Chromosomal location plays a role in regulation of aflatoxin gene expression in Aspergillus parasiticus. Appl Environ Microbiol (2002) 1.31
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
Concussion in professional football: players returning to the same game--part 7. Neurosurgery (2005) 1.28
The impact of trauma-focused group therapy upon HIV sexual risk behaviors in the NIDA Clinical Trials Network "Women and trauma" multi-site study. AIDS Behav (2009) 1.28
Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther (2007) 1.28
Annotare--a tool for annotating high-throughput biomedical investigations and resulting data. Bioinformatics (2010) 1.26
Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend (2008) 1.25
Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs (2011) 1.25
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther (2005) 1.25
Law enforcement practices associated with HIV infection among injection drug users in Odessa, Ukraine. AIDS Behav (2013) 1.25
Brief strategic family therapy versus treatment as usual: results of a multisite randomized trial for substance using adolescents. J Consult Clin Psychol (2011) 1.23
Concussion in professional football: injuries involving 7 or more days out--Part 5. Neurosurgery (2004) 1.21